Cellectar Biosciences CLRB 深 沪
等待开盘 09-16 09:30:00 美东时间
5.08
0.000
0.00%
华盛通- 最 高5.2323
- 今 开5.15
- 成交量 3.58万股
- 最 低 5.07
- 昨 收 5.08
- 总市值 1621.54万
- 52周最高 67.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.11
- 委 比 96.12%
- 总股本 319.20万
- 历史最高 276000.00
- 量 比 0.43
- 振 幅 3.19%
- 历史最低 5.07
- 每 手 1
- 风险率 22.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
Cellectar Biosciences和ITM Isotope Technologies Munich SE达成协议，确保Actinium-225（Ac-225）的供应，用于开发治疗实体瘤的放射性药物CLR 121225。Cellectar利用其独特的磷酸脂醚（PLE）平台，而ITM与加拿大核实验室合资的Actineer™ Inc.将生产Ac-225，以满足临床需求。该协议旨在解决Ac-225供应不足的问题，推动精准放射治疗的发展，改善癌症患者的治疗效果。
09-11 12:05
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
Cellectar Biosciences announced progress with EMA regarding a potential Conditional Marketing Authorization submission for iopofosine I 131 to treat Waldenstrom Macroglobulinemia (WM) in the EU, with a decision expected in late 3Q25/Early 4Q25. The company also plans to pursue accelerated FDA approval for iopofosine I 131 as a WM treatment in the U.S., subject to additional funding and confirmatory trial initiation. Cellectar will advance its Aug...
09-09 12:05
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
Cellectar Biosciences' COO, Jarrod Longcor, will participate in multiple medical meetings in September, discussing topics including ADCs, radiopharmaceuticals, supply chain barriers, and pediatric cancer treatments. The company focuses on developing cancer drugs using its Phospholipid Drug Conjugate™ platform, currently advancing assets like iopofosine I 131 and CLR 121225. These programs target incurable cancers and have received various regulat...
09-05 12:45
Cellectar Biosciences To Present Preclinical Data On Novel Pancreatic Cancer Therapy At AACR Conference
Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for
09-03 20:08
Cellectar To Present Interim Phase 1b Data On Iopofosine In Pediatric Brain Cancer At AACR Conference
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for
08-27 20:09
Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
Cellectar Biosciences announced the acceptance of an abstract for oral presentation at the AACR Special Conference on Pediatric Cancer, focusing on interim data from the Phase 1b study of iopofosine I 131 in relapsed/refractory pediatric high-grade glioma (r/r pHGG) patients. The presentation will highlight the clinical potential of iopofosine I 131 and discuss safety, tolerability, and efficacy in pediatric patients. The study aims to optimize d...
08-27 12:05
Cellectar Biosciences Q2 EPS $(3.39) Beats $(3.98) Estimate
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(3.39) per share which beat the analyst consensus estimate of $(3.98) by 14.72 percent. This is a 37.22 percent increase over losses of $(5.40) per share
08-14 19:22
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
A Peek at Cellectar Biosciences's Future Earnings
Cellectar Biosciences (NASDAQ:CLRB) is preparing to release its quarterly earni...
08-14 00:03
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025
Cellectar Biosciences Inc. will release its Q2 2025 financial results and provide a corporate update on August 14, 2025, at 8:30 a.m. ET. The conference call includes a toll-free number (1-800-717-1738) and a webcast link. Cellectar focuses on developing cancer treatments using its Phospholipid Drug Conjugate™ (PDC) platform, with key programs like iopofosine I 131, CLR 121225, and CLR 121125 in clinical trials, receiving multiple FDA designation...
08-07 12:05
